Skip to content
Tablet Allopathic

Dinoges-EV 2 mg+2 mg tablet

Generic: Dienogest + Estradiol Valerate

Company: Not listed yet. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength2 mg+2 mg
PackNot listed yet

Reviewed by: not listed yet. Source: not listed yet.

Last updated September 7, 2024.

Compare

Same generic, same strength

Sorted by price per tablet. Ask your pharmacist before you switch brands.

Dienogest + Estradiol Valerate 2 mg+2 mg tablets

Prices as listed on BestinMeds.

No price is listed for this strength yet.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Dienogest + Estradiol Valerate guide

Indications

Contraception This is an estrogen/progestin COC, indicated for use by women to prevent pregnancy. The efficacy of this tablet in women with a body mass index (BMI) of >30 kg/m 2 has not been evaluated. Treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception.

Dosage and administration

Take one tablet daily by mouth at the same time every day. Tablets must be taken in the order directed on the blister pack. Do not skip or delay intake by more than 12 hours. 

Side effects

The most common adverse reactions (≥2%) in clinical trials for Natazia are headache (including migraines) 13%, breast pain 7%, menstrual disorders 7%, nausea or vomiting 6%, acne 4%, mood changes (3%) and increased weight 3%.

Precautions and warnings

Vascular risks: Stop this tablet if a thrombotic event occurs. Stop this tablet at least 4 weeks before and through 2 weeks after major surgery. Start this tablet no earlier than 4 weeks after delivery, in women who are not breastfeeding. Liver disease: Discontinue this tablet if jaundice occurs. High blood pressure: Do not prescribe this tablet for women with uncontrolled hypertension or hypertension with vascular disease. Carbohydrate and lipid metabolic effects: Monitor prediabetic and diabetic women taking this tablet. Consider an alternate contraceptive method for women with uncontrolled dyslipidemia. Headache: Evaluate significant change in headaches and discontinue this tablet if indicated. Uterine bleeding: Evaluate irregular bleeding or amenorrhea. CYP3A4 induction: Women taking strong CYP3A4 inducers (for example, carbamazepine, phenytoin, rifampicin, and St. John’s wort) should not choose this tablet as their oral contraceptive due to the possibility of decreased contraceptive efficacy.

Pregnancy and lactation

This information is not available. Ask your doctor or pharmacist.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250